v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured on a Recurring Basis
The following represents assets and liabilities measured at fair value on a recurring basis by the Company (in thousands):
June 30, 2026Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$15,560 $15,560 $— $— 
Investment in iECURE744 — — 744 
Imugene Marketable Securities1,473 1,473 — — 
$17,777 $17,033 $— $744 
Liabilities:
Final payment fee$187 $— $187 $— 
Warrant liability36,693 — — 36,693 
$36,880 $— $187 $36,693 
December 31, 2025Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$15,286 $15,286 $— $— 
Investment in iECURE744 — — 744 
Imugene Marketable Securities4,762 4,762 — — 
$20,792 $20,048 $— $744 
Liabilities:
Final payment fee$208 $— $208 $— 
Warrant Liability15,695 — — 15,695 
$15,903 $— $208 $15,695 
Summary of Financial Assets Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs
The following represents a reconciliation of assets measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) for the six months ended June 30, 2026 (in thousands). The warrant reconciliation is disclosed in Note 11, Warrants:
Investment in iECURE
Balance December 31, 2025$744 
(Loss) gain from changes in fair value included in earnings— 
Balance June 30, 2026$744